ClinicalTrials.gg
RecruitingNCT06918132N-PLANCUpdated Oct 29, 2026

Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer

A Phase 2 interventional study of Biospecimen Collection and Cemiplimab in Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer AJCC v8 and Stage II Lung Cancer AJCC v8, sponsored by Mayo Clinic. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Mayo Clinic · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Oct 29, 2026Eligibility revisedStudy contact changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung — 19 open to participants now, 23 under way, 4 of them phase 3. cemiplimab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
17th of 30
60 · median 62
Started
2025
with 9 others
Phase 2
19 of 30
13 open now
Primary completion
2030-12
later than 19 of 22 live
Registered
20th of 30
by date

Among the 30 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, this one is the 17th largest by planned enrollment, is one of 10 that started in 2025, is one of 19 in phase 2, reaches primary completion later than 19 of the 22 other live ones, and was the 20th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

19 of the 30 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

About cemiplimab

cemiplimab: first FDA approval 2018 (LIBTAYO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This phase II trial tests how well a fixed dose combination (FDC) of cemiplimab and fianlimab before surgery (neoadjuvant) works in treating patients with stage IB-IIIB non-small cell lung cancer (NSCLC). The current standard of care (SOC) for NSCLC is to give chemotherapy and immunotherapy before going to surgery to have the cancer removed (neoadjuvant therapy). Immunotherapy with monoclonal antibodies, such as cemiplimab and fianlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving a FDC of cemiplimab and fianlimab before surgery may kill more tumor cells in treating patients with stage IB-IIIB NSCLC.

Read the detailed description

PRIMARY OBJECTIVES:

I. To assess efficacy of neoadjuvant cemiplimab and fianlimab in patients with resectable/early-stage NSCLC with PD-L1 1-49%, as measured by rate of major pathologic response (MPR) (defined as ≤ 10% viable tumor cells in resected tumor and lymph nodes).

II. To assess efficacy of neoadjuvant cemiplimab and fianlimab in patients with resectable/early-stage NSCLC with PD-L1 ≥ 50%, as measured by rate of major pathologic response (MPR).

SECONDARY OBJECTIVES:

I. Assess the following endpoints (overall and by PD-L1 subsets): event-free survival (EFS), overall survival (OS), disease-free survival (DFS), response rate, pathological complete response rate (pCR), surgical feasibility, and adverse events.

OTHER GOALS (done overall and by PD-L1 subsets):

I. Assess the following in an exploratory fashion: residual viable tumor cells using various cutpoints, whole exome sequencing (WES), gene copy number analysis, circulating tumor deoxyribonucleic acid (DNA) (ctDNA) analysis, tumor microenvironment (TME) analysis, microbiome analyses, temporal biomarker changes.

II. Assess LAG-3 expression on immune-cells by immunohistochemistry (IHC) (17B4) and MHC-II and FGL1 expression by on tumor cells and correlate with clinical data like MPR rate, EFS, and OS.

III. Determine any correlation between the above biomarkers with clinical data of interest like the MPR rate, EFS, and OS.

IV. Determine ctDNA testing as a marker for minimal residual disease (MRD) and molecular recurrence.

V. Determine radiomic and pathomic markers of response to therapy.

OUTLINE:

Patients receive cemiplimab intravenously (IV) over 30 minutes on day 1 of each cycle and fianlimab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo magnetic resonance imaging (MRI) during screening, tissue sample collection on study, and blood sample collection, computed tomography (CT), and positron emission tomography (PET)/CT throughout the study. Patients may undergo SOC surgery post-treatment.

After completion of study treatment, patients are followed up at 90 days, then every 3 months post-surgery for the first 2 years, then every 6 months for up to 5 years.

03

Conditions studied

  • Lung Non-Small Cell Carcinoma
  • Stage IB Lung Cancer AJCC v8
  • Stage II Lung Cancer AJCC v8
  • Stage IIIA Lung Cancer AJCC v8
  • Stage IIIB Lung Cancer AJCC v8
04

Who can participate

The criteria were revised on the registry on Oct 29, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Disease characteristics:

    • or cytologically confirmed stage IB-IIIB (N2) non-small cell lung cancer (NSCLC) per American Joint Committee on Cancer (AJCC) Cancer Staging Manual Eighth Edition
    • T4 tumors will only be eligible if they are defined as T4 based only on their size (more than 7 cm). All other T4 tumors will be ineligible.
    • Pathologic status of lymph nodes must be known for suspicious or enlarged lymph nodes. Note: suspicious or enlarged lymph nodes must be discussed with sponsor/principal investigator.
    • expression ≥ 1% by tumor proportion score (TPS) using immunohistochemistry (IHC)

      • Group A: PD-L1 expression ≥ 1% \< 50%
      • Group B: PD-L1 expression ≥ 50%
    • Complete surgical resection of the primary NSCLC must be deemed achievable by thoracic surgeon at screening
  • per (RECIST) v1.1 NOTE: Tumor lesions in a previously irradiated area are not considered measurable disease; Disease that is measurable by physical examination only is not eligible
  • (ECOG) performance status (PS) 0 or 1
  • Adequate pulmonary function ascertained by treating surgeon obtained ≤ 42 days prior to registration. A pre- or post-bronchodilator (FEV1) of 1.0 L or > 40% postoperative predicted value or diffusing capacity of the lungs for carbon monoxide (DLCO) > 40% predicted value are required prior to enrollment
  • ≥ 8.0 g/dL (obtained ≤ 15 days prior to registration)
  • (ANC) ≥ 1500/mm\^3 (obtained ≤ 15 days prior to registration)
  • count ≥ 100,000/mm\^3 (obtained ≤ 15 days prior to registration)
  • Total ≤ 1.5 x (ULN) (obtained ≤ 15 days prior to registration)
  • (ALT) and aspartate transaminase (AST) ≤ 3 x ULN (obtained ≤ 15 days prior to registration)
  • (PT)/international normalized ratio (INR)/activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN OR if patient is receiving anticoagulant therapy and INR or aPTT is within target range of therapy (obtained ≤ 15 days prior to registration)
  • Calculated ≥ 45 ml/min using the Cockroft-Gault formula (obtained ≤ 15 days prior to registration)
  • Negative pregnancy test done ≤ 8 days prior to registration, for persons of only
  • Provide written
  • Willingness to provide mandatory blood specimens for correlative research
  • Willingness to provide mandatory tissue blocks and slides for correlative research
  • Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)

Exclusion criteria

Exclusion Criteria:

  • Any of the following because this study involves an agent, the genotoxic, mutagenic, and teratogenic effects of which on the developing fetus and newborn are unknown:

    • Pregnant persons
    • Nursing persons
    • Persons of or able to father a child who are unwilling to employ highly effective during the study and up to 6 months after the last dose
  • Presence of targetable alterations [Epiderman Growth Factor Receptor (EGFR), anaplastic lymphoma kinase (ALK), receptor tyrosine kinase (ROS1)] in tumor or circulating tumor DNA
  • Unresectable or disease
  • Active or history of the following:

    • Prior systemic anti-cancer therapy or radiation therapy for the same cancer being studied in this protocol
    • Interstitial lung disease (e.g., idiopathic pulmonary fibrosis or organizing pneumonia), or active, noninfectious pneumonitis that required immune-suppressive doses of to assist with management, or pneumonitis within the last 5 years
    • disease (including any history of inflammatory bowel disease)
    • Any syndrome that required systemic steroids or medications EXCEPTIONS: patients with vitiligo; resolved childhood asthma/atopy; residual hypothyroidism that requires only hormone replacement; or psoriasis not requiring systemic treatment, type-1 diabetes mellitus, or rheumatoid arthritis managed without disease modifying anti-rheumatic drugs or >10 mg prednisone equivalent
  • Patients requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications ≤14 days prior to registration.

NOTE: Inhaled or topical steroids and adrenal replacement doses \< 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease

  • Patients with organ transplantation
  • History of myocardial infarction ≤ 6 months prior to registration, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias; or prior immune-related myocarditis
  • Uncontrolled intercurrent non-cardiac illness including, but not limited to:

    • Ongoing or active infection
    • Psychiatric illness/social situations
    • Dyspnea at rest due to complications of advanced or other disease that requires continuous oxygen therapy
    • Any other conditions that would limit compliance with study requirements
  • Uncontrolled infection with , virus (HBV), or virus (HCV) or diagnosis of immunodeficiency that is related to, or results in chronic infection.

Note: No testing is required for this study unless mandated by local health authority.

EXCEPTIONS:

  • Patients with known HIV who have controlled infection [undetectable viral load and cluster of differentiation 4 (CD4) count above 350 either spontaneously or on a stable antiviral regimen] are permitted. For patients with controlled HIV infection, monitoring will be performed per local standards.
  • Patients with known hepatitis B (hepatitis B surface antigen positive [HBsAg+]) who have controlled infection (serum hepatitis B virus DNA polymerase chain reaction (PCR) that is below the limit of detection AND receiving anti-viral therapy for hepatitis B) are permitted. Patients with controlled infections must undergo periodic monitoring of HBV DNA per local standards and must remain on anti-viral therapy for at least 6 months beyond the last dose of investigational study drug.
  • Patients who are known hepatitis C virus antibody positive (HCV Ab+) who have controlled infection (undetectable HCV ribonucleic acid (RNA) by PCR either spontaneously or in response to a successful prior course of anti-HCV therapy) are permitted.
  • Patients with HIV or hepatitis must be reviewed by a qualified specialist (e.g., infectious disease or hepatologist) managing this disease prior to commencing and regularly throughout the duration of their participation in the trial NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial

    • Receiving any other investigational agent which would be considered as a treatment for the primary malignancy
    • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
    • Patients with a prior or concurrent malignancy whose natural history or treatment does have the potential to interfere with the safety or efficacy assessment of the investigational regimen
    • Known to the active substances or to any of the
    • Receipt of ≤ 30 days prior to registration
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Treatment (cemiplimab, fianlimab)

    Patients receive cemiplimab IV over 30 minutes on day 1 of each cycle and fianlimab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo MRI during screening, tissue sample collection on study, and blood sample collection, CT, and PET/CT throughout the study. Patients may undergo SOC surgery post-treatment.

    Procedure: Biospecimen Collection · Biological: Cemiplimab · Biological: Fianlimab · Procedure: Magnetic Resonance Imaging · Procedure: Surgical Procedure · Procedure: Computed Tomography · Procedure: Positron Emission Tomography

Interventions

  • ProcedureBiospecimen Collection

    Undergo tissue and blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • BiologicalCemiplimab

    Given IV

    Also known as: Cemiplimab RWLC, Cemiplimab-rwlc, Libtayo, REGN 2810, REGN-2810, REGN2810

  • BiologicalFianlimab

    Given IV

    Also known as: Anti-LAG-3 MoAb REGN3767, REGN 3767, REGN3767, WHO 11182

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI

  • ProcedureSurgical Procedure

    Undergo SOC surgery

    Also known as: Operation, Surgery, Surgery Type, Surgery, Not Otherwise Specified (NOS), Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery

  • ProcedureComputed Tomography

    Undergo CT and PET/CT

    Also known as: CAT, CAT Scan, Computed Axial Tomography, computerized axial tomogrpahy, Computerized Axial Tomography, Computerized Tomography, Computerized Tomography (CT) scan, CT, Ct Scan, Diagnostic CAT Scan

  • ProcedurePositron Emission Tomography

    Undergo PET/CT

    Also known as: Medical Imaging, PET, Pet Scan, positron emission tomography scan

06

What researchers measure

Primary outcomes

  1. Major pathologic response (MPR) rate (Group A)

    Will be defined as ≤ 10% viable tumor cells in resected tumor and lymph nodes. Will be conducted using two parallel Simon two-stage trial designs. Will be evaluated within the PD-L1 1-49% group.

    Time frame: Up to 2 years

  2. MPR rate (Group B)

    Will be defined as ≤ 10% viable tumor cells in resected tumor and lymph nodes. Will be conducted using two parallel Simon two-stage trial designs. Will be evaluated within the PD-L1 ≥ 50% group.

    Time frame: Up to 2 years

Secondary outcomes

  1. Event-free survival (EFS)

    Defined as the time from study entry to any progression of disease precluding surgery, progression or recurrence of disease after surgery, progression of disease in the absence of surgery, or death from any cause (whichever occurs first).

    Time frame: Up to 5 years

  2. Overall survival (OS)

    Defined as the time from study entry to death from any cause.

    Time frame: Up to 5 years

  3. Disease-free survival (DFS)

    Defined as the time from surgery to the first of either disease recurrence or death from any cause.

    Time frame: Up to 5 years

  4. Overall response rate (ORR)

    Will be calculated based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. A tumor response is defined to be either a complete response or partial response noted as the objective status during neoadjuvant treatment.

    Time frame: Up to 5 years

  5. Pathologic complete response (pCR) rate

    Defined as 0% residual viable tumor (complete absence of tumor) in the resected lung and lymph node tissue. Will be reported as pCR rate, defined as the proportion of patients who achieve pCR after neoadjuvant treatment at the time of resection

    Time frame: Up to 5 years

  6. Surgical feasibility - to surgery

    Will be assessed by the number of participants who make it to surgery

    Time frame: Up to 5 years

  7. Surgical feasibility - complete surgery

    Will be assessed by the number of participants who complete surgery

    Time frame: Up to 5 years

  8. Incidence of adverse events

    The maximum grade for each type of adverse event will be summarized using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Frequency and percentage of Grade 3+ adverse events will be summarized.

    Time frame: Up to 90 days after last study treatment, up to 2 years

07

Study locations

2 of 2 sites recruiting
  • Mayo Clinic in Florida
    Jacksonville, Florida 32224-9980, United States
    Recruiting
    • Cancer Center Clinical Trials · Contact507-293-6386
    • Vamsi Velcheti, MD · Principal investigator
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
    Recruiting
    • Clinical Trials Referral Office · Contactmayocliniccancerstudies@mayo.edu · 855-776-0015
    • Cancer Center Clinical Trials · Contact507-293-6386
    • Kaushal Parikh, MBBS · Principal investigator
08

References and documents

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2030, 67 months after the start.

Of 732 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's planned 67 months is above that.

Counting every sponsor, half of 1,049 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: start Apr 2025 → May 2025, primary completion Apr 2027 → Dec 2030 and completion Apr 2027 → Dec 2033.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2025
First posted
Apr 9, 2025
StartActual
May 2, 2025was Apr 2025
Primary completionEst.
Dec 2, 2030was Apr 2027
CompletionEst.
Dec 2, 2033was Apr 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Mayo Clinic in Florida · Jacksonville, United States
Oct 29, 2026
Start date
Apr 29, 2025→May 2, 2025
Oct 1, 2026
Primary completion
Apr 29, 2027→Dec 2, 2030
Oct 1, 2026
Study completion
Apr 29, 2027→Dec 2, 2033
Oct 1, 2026
Eligibility
2 inclusion criteria edited; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedAdequate pulmonary function ascertained by treating surgeon obtained ≤ 3042 days prior to registration. A pre- or post-bronchodilator forced expiratory volume in 1 second (FEV1) of 1.0 L or > 40% postoperative predicted value or diffusing capacity of the lungs for carbon monoxide (DLCO) > 40% predicted value are required prior to enrollment
  • EditedWillingness to provide mandatory tissue specimensblocks and slides for correlative research
Exclusion criteria
  • EditedPresence of targetable alterations [Epiderman Growth Factor Receptor (EGFR), anaplastic lymphoma kinase (ALK), receptor tyrosine kinase (ROS1)] in tumor or circulating tumor DNA
Oct 29, 2026
Contact
Study contact changed: added •••6386. See the current contact
Oct 29, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Mayo Clinic in Rochester · Rochester, United StatesContact added •••6386
Oct 29, 2026
Show all 2 updates
  1. Oct 29, 2026
    1 site added
    Show site
    • Mayo Clinic in Florida · Jacksonville, United States
    Eligibility 2 inclusion criteria edited; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedAdequate pulmonary function ascertained by treating surgeon obtained ≤ 3042 days prior to registration. A pre- or post-bronchodilator forced expiratory volume in 1 second (FEV1) of 1.0 L or > 40% postoperative predicted value or diffusing capacity of the lungs for carbon monoxide (DLCO) > 40% predicted value are required prior to enrollment
    • EditedWillingness to provide mandatory tissue specimensblocks and slides for correlative research
    Exclusion criteria
    • EditedPresence of targetable alterations [Epiderman Growth Factor Receptor (EGFR), anaplastic lymphoma kinase (ALK), receptor tyrosine kinase (ROS1)] in tumor or circulating tumor DNA
    Contact Study contact changed: added •••6386. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Mayo Clinic in Rochester · Rochester, United StatesContact added •••6386
    + 3 other changes: verification date, responsible party and description
  2. Oct 1, 2026
    Start date Apr 29, 2025→May 2, 2025
    Primary completion Apr 29, 2027→Dec 2, 2030
    Study completion Apr 29, 2027→Dec 2, 2033
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06918132
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
Apr 9, 2025
Start date
May 2, 2025
Primary completion
Dec 2, 2030 (estimated)
Completion
Dec 2, 2033 (estimated)
Last update
Oct 29, 2026

Study contacts

Clinical Trials Referral Office
Contact
mayocliniccancerstudies@mayo.edu
855-776-0015
Cancer Center Clinical Trials
Contact
507-293-6386
Kaushal Parikh, MBBS
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cemiplimab · Fianlimab

Start the discussion